VisEn Medical has commercially launched its new Cat-K FAST molecular imaging agent used in tracking Cathepsin K activity, a biomarker and therapeutic target in bone-related diseases, including cancer metastasis to the bone and atherosclerosis. The new agent is expected to help improve research and drug development through the real-time imaging of Cat-K activity.

Full Story:
PR Newswire

Related Summaries